Navigation Links
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Date:10/17/2007

onically debilitating condition that affects no more than five in 10,000 persons in the European Union.

About Picoplatin

Picoplatin is a new generation platinum chemotherapy agent. It was designed to overcome platinum resistance and to prolong the time to relapse after chemotherapy in the treatment of solid tumors, and to have an improved safety profile compared with existing platinum-based chemotherapeutics. Poniard received orphan drug designation from the FDA in November 2005 for picoplatin for the treatment of SCLC.

In addition to the SPEAR trial of intravenous picoplatin in SCLC, Poniard is also evaluating intravenous picoplatin in an ongoing Phase 1 clinical trial as a first-line treatment for metastatic colorectal cancer and in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

About Small Cell Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, but many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for th
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... Utah , July 10, 2014 /PRNewswire-iReach/ ... annotation and interpretation, today announced an agreement ... (NGS) analytics for Lineagen,s NextStep Dx ... of neurodevelopmental and neurological disorders, currently offers ... microarray (CMA) testing service used by healthcare ...
(Date:7/10/2014)... fight against terrorism with the creation of a sensor ... use of light and special glass fibres. , Published ... , the researchers describe a novel optical fibre sensor ... 6.3 ppm (parts per million). It requires an analysis ... detection has involved looking for metals that encase them ...
(Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... 5 - Evoke Pharma, Inc., a privately-held specialty ... Phase 2b clinical trial to evaluate EVK-001 for the ... is a syndrome characterized by delayed emptying of the ... absence of mechanical obstruction. Diabetes is an important cause ...
... Study Published in the Journal of Rheumatology Examines ... Gout PatientsEAST BRUNSWICK, N.J., May 5 Savient ... today the print publication of the Savient-supported longitudinal ... gout (TFG). The objective of the study was ...
... Milestone Payment from GlaxoSmithKlineMOUNTAIN VIEW, Calif., May 5 ... identified an orally bioavailable small molecule antagonist of ... clinical development. The acceptance of the molecule ... milestone payment from the alliance with GlaxoSmithKline (NYSE: ...
Cached Biology Technology:Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 3Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 2Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 3Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 4ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 3ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 4
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... geology as in cancer research, the silver bullet theory always ... wrong. For geologists who study mass extinctions, the silver ... an asteroid is the prime suspect only in the most ... Bottjer. The cataclysm 65 million years ago wiped out the ...
... PORTLAND, Ore. The National Institutes of Health has ... American scientists led by Oregon Health & Science University ... biofuels technology from marine mollusks for development in the ... Philippine archipelago whose waters are inhabited by an estimated ...
... Based on its recent,analysis of the noninvasive ... with the 2008 North American Award for Technology,Innovation ... optics-based,stand-off iris recognition system., The innovative iris ... identify a subject,s iris at a stand-off,distance of ...
Cached Biology News:Extinction by asteroid a rarity 2Discovering drugs, biofuels in tropical seas 2Discovering drugs, biofuels in tropical seas 3Discovering drugs, biofuels in tropical seas 4Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 2Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 3Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 4
Alexa Fluor 647 anti-mouse Qa-2...
... The Luminex 100 Instrument System is ... assays using Upstate's Beadlyte reagents. The ... Dell computer with software version 1.7, ... Delivery System. Upstate offers $2000 in ...
EDG-6 Lysate Source: Cell Lysate Application: Western Blotting Control Form: IgG...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Biology Products: